AstraZeneca: Imfinzi is the First and Only Immunotherapy to Show Survival Benefit in Limited-Stage Small Cell Lung Cancer in Global Phase III Trial, Reducing the Risk of Death by 27% vs. Placebo
June 04, 2024
June 04, 2024
WILMINGTON, Delaware, June 4 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 3, 2024:
Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who . . .
Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who . . .